loading
Precedente Chiudi:
$642.59
Aprire:
$639.24
Volume 24 ore:
994.80K
Relative Volume:
1.34
Capitalizzazione di mercato:
$66.98B
Reddito:
$14.92B
Utile/perdita netta:
$4.42B
Rapporto P/E:
15.57
EPS:
41.0422
Flusso di cassa netto:
$3.79B
1 W Prestazione:
-8.50%
1M Prestazione:
-14.43%
6M Prestazione:
-15.48%
1 anno Prestazione:
+7.04%
Intervallo 1D:
Value
$632.72
$644.12
Intervallo di 1 settimana:
Value
$610.60
$651.00
Portata 52W:
Value
$476.49
$821.11

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Name
Nome
Regeneron Pharmaceuticals Inc
Name
Telefono
(914) 847-7000
Name
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Name
Dipendente
15,410
Name
Cinguettio
@regeneron
Name
Prossima data di guadagno
2026-04-29
Name
Ultimi documenti SEC
Name
REGN's Discussions on Twitter

Compare REGN vs VRTX, ARGX, ALNY, RVMD

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
REGN icon
REGN
Regeneron Pharmaceuticals Inc
638.88 67.37B 14.92B 4.42B 3.79B 41.04
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
434.52 110.03B 12.34B 4.34B 3.71B 16.87
ARGX icon
ARGX
Argen X Se Adr
806.46 50.76B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
297.45 40.12B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
151.56 32.68B 742.00K -1.37B -1.07B -7.0731

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2026-03-31 Ripresa Piper Sandler Overweight
2026-03-06 Iniziato Barclays Overweight
2026-01-07 Aggiornamento BofA Securities Underperform → Buy
2025-12-03 Downgrade Morgan Stanley Overweight → Equal-Weight
2025-11-24 Iniziato HSBC Securities Buy
2025-11-24 Ripresa Truist Buy
2025-11-13 Iniziato Scotiabank Sector Perform
2025-08-14 Iniziato Rothschild & Co Redburn Buy
2025-06-30 Downgrade Argus Buy → Hold
2025-05-30 Downgrade RBC Capital Mkts Outperform → Sector Perform
2025-05-30 Downgrade Wells Fargo Overweight → Equal Weight
2025-05-14 Aggiornamento Citigroup Neutral → Buy
2025-04-22 Ripresa Cantor Fitzgerald Overweight
2025-02-05 Aggiornamento Leerink Partners Market Perform → Outperform
2025-01-16 Downgrade UBS Buy → Neutral
2024-12-10 Ripresa BofA Securities Underperform
2024-11-15 Iniziato Wolfe Research Outperform
2024-11-14 Iniziato Citigroup Neutral
2024-09-24 Downgrade Leerink Partners Outperform → Market Perform
2024-03-12 Iniziato Bernstein Outperform
2024-01-12 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2023-11-09 Iniziato Deutsche Bank Hold
2023-11-03 Aggiornamento Raymond James Mkt Perform → Outperform
2023-08-21 Aggiornamento Canaccord Genuity Hold → Buy
2023-08-21 Reiterato Oppenheimer Perform
2023-06-28 Downgrade Canaccord Genuity Buy → Hold
2023-03-27 Aggiornamento SVB Securities Market Perform → Outperform
2023-03-24 Aggiornamento Jefferies Hold → Buy
2023-03-23 Aggiornamento Raymond James Underperform → Mkt Perform
2023-01-30 Aggiornamento Cowen Market Perform → Outperform
2023-01-20 Aggiornamento JP Morgan Neutral → Overweight
2022-10-26 Downgrade Raymond James Mkt Perform → Underperform
2022-10-17 Downgrade Evercore ISI Outperform → In-line
2022-09-09 Aggiornamento Jefferies Underperform → Hold
2022-09-09 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2022-07-25 Downgrade SVB Leerink Outperform → Mkt Perform
2022-07-13 Iniziato Cantor Fitzgerald Neutral
2022-06-06 Iniziato Jefferies Underperform
2022-05-23 Iniziato SVB Leerink Outperform
2022-01-05 Downgrade BofA Securities Neutral → Underperform
2022-01-03 Aggiornamento Bernstein Mkt Perform → Outperform
2021-12-15 Downgrade Bernstein Outperform → Mkt Perform
2021-12-09 Ripresa Wells Fargo Overweight
2021-12-07 Ripresa Cowen Market Perform
2021-12-06 Iniziato Goldman Buy
2021-11-19 Ripresa BMO Capital Markets Outperform
2021-11-05 Downgrade The Benchmark Company Buy → Hold
2021-06-29 Iniziato H.C. Wainwright Buy
2021-01-25 Aggiornamento BMO Capital Markets Market Perform → Outperform
2021-01-13 Aggiornamento The Benchmark Company Hold → Buy
2021-01-08 Aggiornamento Citigroup Neutral → Buy
2020-10-05 Aggiornamento Cantor Fitzgerald Neutral → Overweight
2020-08-20 Downgrade The Benchmark Company Buy → Hold
2020-07-09 Aggiornamento SunTrust Hold → Buy
2020-05-26 Aggiornamento Wells Fargo Equal Weight → Overweight
2020-04-28 Downgrade Citigroup Buy → Neutral
2020-04-17 Aggiornamento The Benchmark Company Hold → Buy
2020-04-08 Iniziato The Benchmark Company Hold
2020-03-31 Iniziato Wolfe Research Peer Perform
2020-02-27 Iniziato Barclays Overweight
2020-02-26 Aggiornamento Canaccord Genuity Hold → Buy
2020-02-26 Downgrade Robert W. Baird Outperform → Neutral
2020-02-25 Aggiornamento Jefferies Hold → Buy
2020-02-11 Aggiornamento Argus Hold → Buy
2019-12-24 Iniziato Raymond James Mkt Perform
2019-12-16 Downgrade Evercore ISI Outperform → In-line
2019-12-13 Aggiornamento Credit Suisse Neutral → Outperform
2019-11-12 Iniziato SunTrust Hold
2019-11-07 Aggiornamento Citigroup Neutral → Buy
2019-10-17 Ripresa BofA/Merrill Neutral
2019-09-23 Aggiornamento Guggenheim Neutral → Buy
Mostra tutto

Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie

pulisher
07:03 AM

Swedbank AB Boosts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

07:03 AM
pulisher
05:53 AM

Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by LSV Asset Management - MarketBeat

05:53 AM
pulisher
02:08 AM

Regeneron R&D Updates Test Market View On Long Term Pipeline Value - Yahoo Finance

02:08 AM
pulisher
May 23, 2026

Stocks making big moves this week: Toll Brothers, Booz Allen Hamilton, Strategy, Regeneron, and Micron - Yahoo Finance

May 23, 2026
pulisher
May 23, 2026

ABN Amro Investment Solutions Cuts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

May 23, 2026
pulisher
May 22, 2026

Lynozyfic AL Amyloidosis Data Gives Regeneron Pipeline And Valuation Focus - simplywall.st

May 22, 2026
pulisher
May 22, 2026

Licensable picture: The exterior of Regeneron Pharmaceuticals May 22, 2026 in Tarrytown. - Reuters Connect

May 22, 2026
pulisher
May 22, 2026

Parabilis Medicines Starts IPO On Promising Cancer Therapy Trials (PBLS) - Seeking Alpha

May 22, 2026
pulisher
May 22, 2026

Regeneron Says Otarmeni Application Accepted Under EU Accelerated Assessment - Moomoo

May 22, 2026
pulisher
May 22, 2026

EMA accepts Regeneron’s gene therapy for rare hearing loss By Investing.com - Investing.com Canada

May 22, 2026
pulisher
May 22, 2026

Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss - The Manila Times

May 22, 2026
pulisher
May 22, 2026

Rx Rundown: Parabilis Medicines, Boston Scientific, Amgen and more - Medical Marketing and Media

May 22, 2026
pulisher
May 22, 2026

(REGN) Movement as an Input in Quant Signal Sets - Stock Traders Daily

May 22, 2026
pulisher
May 21, 2026

symbol__ Stock Quote Price and Forecast - CNN

May 21, 2026
pulisher
May 21, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc.REGN - PR Newswire

May 21, 2026
pulisher
May 21, 2026

Regeneron reports positive trial results for amyloidosis treatment By Investing.com - Investing.com Canada

May 21, 2026
pulisher
May 21, 2026

Regeneron Pharmaceuticals Reports Encouraging LINKER-AL2 Trial Results for Lynozyfic® in Systemic AL Amyloidosis - Quiver Quantitative

May 21, 2026
pulisher
May 21, 2026

Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch

May 21, 2026
pulisher
May 21, 2026

Regeneron Pharmaceuticals, Inc. Cash Flow – BVL:REGNUS - TradingView

May 21, 2026
pulisher
May 21, 2026

Jim Cramer on Regeneron: “There Could Be Some More Downgrades” - Insider Monkey

May 21, 2026
pulisher
May 21, 2026

CytomX Therapeutics to Present at Upcoming June Investor Conferences - GlobeNewswire Inc.

May 21, 2026
pulisher
May 20, 2026

Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

May 20, 2026
pulisher
May 20, 2026

Regeneron backed Parabilis Medicines seeks U.S. IPO - Seeking Alpha

May 20, 2026
pulisher
May 20, 2026

Why Regeneron (REGN) Shares Are Trading Lower Today - Yahoo Finance

May 20, 2026
pulisher
May 20, 2026

REGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud - Business Wire

May 20, 2026
pulisher
May 20, 2026

After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets - Yahoo Finance

May 20, 2026
pulisher
May 20, 2026

Tredje AP fonden Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

May 20, 2026
pulisher
May 20, 2026

Resona Asset Management Co. Ltd. Has $24.71 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

May 20, 2026
pulisher
May 20, 2026

ProShare Advisors LLC Has $142.25 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

May 20, 2026
pulisher
May 20, 2026

Fideuram Intesa Sanpaolo Private Banking S.P.A. Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

May 20, 2026
pulisher
May 20, 2026

Harvest Portfolios Group Inc. Has $63.10 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

May 20, 2026
pulisher
May 19, 2026

Scotiabank Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $770 - Moomoo

May 19, 2026
pulisher
May 19, 2026

Research Alert: CFRA Lowers Rating On Shares Of Regeneron Pharmaceuticals, Inc To Hold From Buy - Moomoo

May 19, 2026
pulisher
May 19, 2026

Regeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2B - Yahoo Finance

May 19, 2026
pulisher
May 19, 2026

Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry? - Yahoo Finance Singapore

May 19, 2026
pulisher
May 19, 2026

A Look At Regeneron Pharmaceuticals (REGN) Valuation After Melanoma Trial Setback And Share Price Pullback - Yahoo Finance

May 19, 2026
pulisher
May 19, 2026

Regeneron Stock Tumbles 12% After Experimental Cancer Drug Misses Key Trial Goal - TIKR.com

May 19, 2026
pulisher
May 19, 2026

REGN Maintained by Canaccord Genuity -- Price Target Lowered to $875 - GuruFocus

May 19, 2026
pulisher
May 19, 2026

Canaccord Genuity Group Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $875.00 - MarketBeat

May 19, 2026
pulisher
May 19, 2026

A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $770 to $968 - Moomoo

May 19, 2026
pulisher
May 19, 2026

Company News for May 19, 2026 - Yahoo Finance

May 19, 2026
pulisher
May 19, 2026

REGN SHAREHOLDER INVESTIGATION: SueWallSt Investigates Regeneron Pharmaceuticals for Possible Securities Law Violations - PR Newswire

May 19, 2026
pulisher
May 19, 2026

Why Regeneron Pharmaceuticals (REGN) Is Down 11.7% After Key Melanoma Combo Trial Missed Its Goal - Yahoo Finance

May 19, 2026
pulisher
May 19, 2026

Canaccord lowers Regeneron stock price target on pipeline concerns By Investing.com - Investing.com Canada

May 19, 2026
pulisher
May 19, 2026

Regeneron teams up with Parabilis to advance novel antibody Helicon - The Pharma Letter

May 19, 2026
pulisher
May 19, 2026

UnitedHealth, Regeneron slip premarket; Dominion Energy, Delta Air Lines jump - Investing.com

May 19, 2026
pulisher
May 19, 2026

Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates - Pharmaceutical Technology

May 19, 2026
pulisher
May 19, 2026

North Dakota State Investment Board Acquires Shares of 3,579 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

May 19, 2026
pulisher
May 19, 2026

Regeneron Pharmaceuticals Inc stock (US7739031091): strategic Parabilis deal after REGN sell-off - AD HOC NEWS

May 19, 2026
pulisher
May 19, 2026

Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Handelsbanken Fonder AB - MarketBeat

May 19, 2026
pulisher
May 19, 2026

Citigroup downgrades Regeneron Pharmaceuticals (REGN) - MSN

May 19, 2026

Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$806.46
price down icon 1.20%
$297.45
price down icon 1.02%
$151.56
price down icon 1.41%
ONC ONC
$310.25
price up icon 0.20%
$54.50
price up icon 1.77%
Capitalizzazione:     |  Volume (24 ore):